These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 25794988

  • 1. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy.
    Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, Loewenstein A, Goldstein M.
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):15-22. PubMed ID: 25794988
    [Abstract] [Full Text] [Related]

  • 2. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study.
    Pitcher JD, Witkin AJ, DeCroos FC, Ho AC.
    Br J Ophthalmol; 2015 Jun; 99(6):848-52. PubMed ID: 25595177
    [Abstract] [Full Text] [Related]

  • 3. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [Abstract] [Full Text] [Related]

  • 4. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, Kneba M, Grzybowski A.
    BMC Ophthalmol; 2019 Jul 25; 19(1):160. PubMed ID: 31345183
    [Abstract] [Full Text] [Related]

  • 5. Oral rifampin for central serous retinopathy: a strategic approach in three patients.
    Pouw AE, Olmos de Koo LC.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan 25; 46(1):98-102. PubMed ID: 25559520
    [Abstract] [Full Text] [Related]

  • 6. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK, Chang CK, Peng CH.
    Retina; 2017 Feb 25; 37(2):325-333. PubMed ID: 27429374
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC, Dijkman G, Boon CJF.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct 25; 255(10):2029-2035. PubMed ID: 28674835
    [Abstract] [Full Text] [Related]

  • 10. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
    Faghihi H, Mohammadzadeh V, Nabavi A, Faghihi S, Kadivar S, Ghassemi F.
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov 01; 50(11):726-733. PubMed ID: 31755972
    [Abstract] [Full Text] [Related]

  • 11. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ, van Dijk EHC, Dijkman G, Boon CJF.
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug 01; 256(8):1395-1402. PubMed ID: 29732468
    [Abstract] [Full Text] [Related]

  • 12. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S.
    Retina; 2013 Feb 01; 33(2):316-23. PubMed ID: 23314238
    [Abstract] [Full Text] [Related]

  • 13. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study.
    Rajesh B, Agrawal H, Peguda HK, Chhablani J.
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jul 01; 49(7):479-486. PubMed ID: 30021034
    [Abstract] [Full Text] [Related]

  • 14. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB, Mohr JK, Ossewaarde-van Norel A, den Hollander AI, Keunen JE, Hoyng CB, Boon CJ.
    Acta Ophthalmol; 2016 Mar 01; 94(2):187-97. PubMed ID: 26670630
    [Abstract] [Full Text] [Related]

  • 15. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
    Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, Tsang CW, Brelén ME.
    Am J Ophthalmol; 2016 Oct 01; 170():91-99. PubMed ID: 27519561
    [Abstract] [Full Text] [Related]

  • 16. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
    Karagiannis D, Parikakis E, Kontomichos L, Batsos G, Chatziralli I.
    Semin Ophthalmol; 2019 Oct 01; 34(6):436-441. PubMed ID: 31309849
    [Abstract] [Full Text] [Related]

  • 17. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.
    Yasui A, Yamamoto M, Hirayama K, Shiraki K, Theisen-Kunde D, Brinkmann R, Miura Y, Kohno T.
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb 01; 255(2):243-254. PubMed ID: 27497611
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy.
    Wuarin R, Kakkassery V, Consigli A, Roquelaure D, Papanastasiou A, Schutz JS, Thumann G, Chronopoulos A.
    Optom Vis Sci; 2019 Jul 01; 96(7):500-506. PubMed ID: 31274738
    [Abstract] [Full Text] [Related]

  • 20. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
    Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M.
    Acta Ophthalmol; 2017 Nov 01; 95(7):e610-e618. PubMed ID: 28653813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.